(2,6-Bis((di(piperidin-1-yl)phosphino)amino)phenyl)palladium(II) chloride

Catalog No. :
ACYBJO422
CAS No. :
955035-37-7
Molecular Formula :
C26H45ClN6P2Pd
Molecular Weight :
645.51

IUPAC Name:(2,6-bis((di(piperidin-1-yl)phosphaneyl)amino)phenyl)palladium(II) chloride

(2,6-Bis((di(piperidin-1-yl)phosphino)amino)phenyl)palladium(II) chloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5g98%$2318.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(2,6-Bis((di(piperidin-1-yl)phosphino)amino)phenyl)palladium(II) chloride
IUPAC Name(2,6-bis((di(piperidin-1-yl)phosphaneyl)amino)phenyl)palladium(II) chloride
MDL No.MFCD17019351
Molecular FormulaC26H45ClN6P2Pd
Molecular Weight645.51
SMILES[Cl-].[Pd+]C1=C(NP(N2CCCCC2)N2CCCCC2)C=CC=C1NP(N1CCCCC1)N1CCCCC1
InChI KeyCSXBAGCRLXPPDX-UHFFFAOYSA-M
Synonym[2,6-Bis[(di-1-piperidinylphosphino)aMino]phenyl]palladiuM(II) chloride;(2,6-Bis((di(piperidin-1-yl)phosphino)amino)phenyl)palladium(II) chloride;[2,6-Bis[(di-1-piperidinylphosphino)amino]phenyl]palladium(II) chloride >=98.0% (AT);[2,6-Bis[(di-1-piperidinylphosphino)aMino]phenyl]palladiuM(II) chloride,98%
CAS No.955035-37-7

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACYBJO422 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACYBJO422 route product structure diagram
    ACYBJO422955035-37-7
Inquiry

2. ACYBJO422 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACYBJO422 route product structure diagram
    ACYBJO422955035-37-7
Inquiry

Comments (0)